Raynaud Phenomenon: Primary and Secondary Causes, Assessment and Treatment Limits

Raynaud phenomenon needs a distinction between brief primary episodes and secondary disease with tissue risk. Confidence is high in that assessment priority. Persistent severe pain, an ulcer or tissue injury needs prompt medical attention; a circulation product cannot establish the cause or protect a threatened digit.

Table of contents

• Evidence summary: distinguish primary from secondary disease
• What Raynaud phenomenon means
• Vessel spasm and the reason secondary disease matters
• Treatment depends on symptoms, cause and tissue risk
• What circulation supplements have not established
• Build a practical trigger and function record
• When a digit needs prompt clinical attention
• Medication review can identify a contributor and a risk
• What investigation can and cannot decide
• Make the care plan specific to your presentation
• Laboratory blood-flow findings are not a clinical verdict
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary: distinguish primary from secondary disease

Raynaud phenomenon is a recognizable episodic circulation problem, but identifying its cause matters. Confidence is high in the need to assess severe or atypical presentations. This review does not establish an independently cleared supplement or compare prescription agents by a sponsor-free effect size.

Clinical guidance for systemic sclerosis is useful context for severe secondary disease. Its authors disclose commercial relationships, and it should not be applied automatically to otherwise uncomplicated primary Raynaud. Original guideline and disclosures.

What Raynaud phenomenon means

Raynaud involves an exaggerated narrowing of small vessels, commonly in fingers or toes, during cold or emotional stress. Primary Raynaud has no identified underlying disease. Secondary Raynaud accompanies another condition, exposure or medicine and can be more severe. NIAMS overview.

Colour can become pale or blue and then change again as circulation returns; not everyone experiences every colour in a fixed sequence. Changes can be harder to see on darker skin, so pain, numbness and the pattern matter too. NHS symptom context.

The diagnostic question is broader than “Do my hands get cold?” Ask whether the episodes fit Raynaud, whether there is evidence of tissue injury, and what raises or lowers concern for a secondary cause.

Vessel spasm and the reason secondary disease matters

Normally, superficial vessels help regulate heat loss. In Raynaud this response can become excessive. In secondary disease, an underlying problem may add structural vessel damage to episodic narrowing; this helps explain why a cold-triggered symptom and an ulcer require different levels of attention. Mechanism context.

Systemic sclerosis is one possible cause, not the diagnosis of everyone with Raynaud. Its care can require assessment of lungs, heart, kidneys and other organs. A blood antibody result alone does not diagnose systemic sclerosis. NIAMS systemic illness assessment.

A positive screening result, a specialist diagnosis and a prediction of future illness are different claims. Ask the clinician to explain which has actually been established and whether further observation is needed.

Treatment depends on symptoms, cause and tissue risk

Initial care commonly addresses cold exposure and other triggers. When symptoms remain troublesome, a clinician may consider a vasodilator such as nifedipine. It is a prescription medicine that relaxes vessels; suitability depends on blood pressure, other conditions and current treatment. Nifedipine context.

Severe secondary disease, persistent ischemia or ulcers need specialist care. NIAMS describes hospital treatment for severe complications. Ask the specialist which interventions apply to the actual diagnosis and what their limitations are. Specialist care context.

Agree on the intended outcome: fewer disruptive episodes, better daily function, healing of an established wound or prevention of new injury. These are not interchangeable. If a medicine causes intolerable symptoms, contact its prescriber rather than substituting a circulation supplement.

What circulation supplements have not established

No supplement is established here as a replacement for assessment, indicated vasodilator treatment or care of a threatened digit. A laboratory claim about nitric oxide, antioxidant activity or “blood flow” does not prove fewer Raynaud attacks or less tissue damage.

A proposed benefit should be judged by the right endpoint: attacks, daily function, wound healing or prevention of injury. This review supplies no independently cleared product comparison. A change in a laboratory marker cannot fill that gap.

Disclose herbal remedies, vitamins and other products, particularly before a procedure or alongside several medicines. Product ingredients and interactions vary. Treating an established nutritional deficiency is a separate clinical indication, not proof of a Raynaud cure. Supplement safety.

Build a practical trigger and function record

Keep a short record of the trigger, affected digits, approximate episode duration and impact on tasks. A photograph during a typical episode can help describe colour changes if it can be taken safely. This is information for an assessment, not a diagnostic test or a reason to delay care.

NIAMS recommends protecting the whole body from cold and using gloves for cold environments such as handling frozen food. Rewarm with warm, rather than hot, water. Avoid direct heat that could burn numb skin. Safe warming.

Consider which daily situations need adaptation: strong air conditioning, wet gloves, refrigerated work or a difficult commute. Ask an occupational clinician about exposures if the problem affects work. Avoiding all activity is not a substitute for finding a workable protection and treatment plan.

When a digit needs prompt clinical attention

Persistent severe pain, an ulcer, infection, a new area of tissue death or a digit that remains unusually pale or blue needs urgent assessment. Severe secondary digital ischemia is not an ordinary brief attack to watch at home. Urgent tissue-risk context.

A one-sided pattern, worsening symptoms, or associated rash, joint pain or weakness warrants medical assessment. NHS guidance also advises assessment when Raynaud first appears after age 30; that is a prompt to investigate, not proof of an autoimmune disease. Assessment triggers.

If the appearance differs substantially from previous episodes, describe the change and duration to the service. An old diagnosis of primary Raynaud should not prevent reassessment of a new wound or persistent circulation problem.

Medication review can identify a contributor and a risk

NIAMS lists medicines that can aggravate vessel narrowing, including certain decongestants, migraine treatments and stimulants. Nicotine, including from vaping, can also constrict vessels. Ask the clinician to review actual names and exposures rather than stopping essential treatment independently. Trigger and medicine review; Nicotine context.

Nifedipine can cause headache, flushing, ankle swelling and other adverse effects. Low blood pressure and concurrent medicines affect suitability; grapefruit and alcohol can increase problems. Tell the prescriber about all medicines and supplements. Current medicine safety.

Discuss smoking cessation with a health professional, including an appropriate cessation aid. A general warning about nicotine does not supply an individualized plan for quitting or justify abandoning a supervised treatment strategy.

What investigation can and cannot decide

History and examination guide testing. Nailfold capillaroscopy and selected blood tests can help assess secondary causes. There is no single definitive Raynaud blood test, and every person does not need every possible autoimmune panel. Diagnostic pathway.

Ask why a test was chosen, what finding would change management, and how an uncertain result will be followed. A normal result today may not explain every future symptom; an abnormal result can also be nonspecific. Interpretation should connect the result with the clinical picture.

For people with a diagnosed systemic disorder, follow its planned organ surveillance as well as the circulation care. Symptom improvement in the hands does not demonstrate that lung or kidney involvement has been excluded. Organ-specific follow-up.

Make the care plan specific to your presentation

Agree on whom to contact for a new ulcer, persistent colour change or medicine intolerance. Record whether the current assessment favours primary Raynaud, secondary Raynaud or an unresolved cause, and what would prompt review.

At follow-up, report both benefit and burden. Is typing, dressing or work easier? Are episodes still frequent? Has a wound healed? Has dizziness or another adverse effect become a limiting problem? These questions make the next consultation more useful than a vague statement that circulation is “better.”

This guide gives no vasodilator dose, drug-combination plan, blood-pressure cutoff or ulcer dressing protocol. Children, pregnancy and complex systemic disease need their own clinical decisions; adult systemic-sclerosis guidance cannot simply be copied into those circumstances.

Laboratory blood-flow findings are not a clinical verdict

Vessel-relaxation experiments can suggest mechanisms. They do not establish safe dosing, long-term symptom relief or protection from digital injury in people. No animal or cell experiment supplies this article’s treatment verdict.

Funding and source roles

The full 2024 BSR original and its author disclosures were opened. No external paper funding does not mean no commercial interests: several authors report company trial, consultancy or speaker support, and BSR offers industry sponsorship. NIAMS has public funding plus a legally authorised Gift Fund, whose complete donors were not audited. These sources support bounded clinical context; neither institutional branding nor a no-external-funding declaration clears every supporting efficacy trial.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Does Raynaud always mean systemic sclerosis?
No. Primary Raynaud has no identified underlying disease; secondary causes require clinical evaluation.

Must the fingers turn white, blue and red?
No. Not everyone has every colour in a fixed order, and skin tone affects visibility.

Can I warm numb fingers with very hot water?
No. NIAMS advises warm rather than hot water; avoid burns.

Does a positive antibody test diagnose the cause?
No. Tests must be interpreted with history, examination and other findings.

Can a circulation supplement replace a vasodilator?
No such replacement is established in this review. Discuss medicines and products with the treating clinician.

Sources and funding notes

NIAMS July 2024 originals, September 2023 systemic-sclerosis education, June 2024 gift authority and current budget page were read. NHS Raynaud is dated July 2023 with a passed July 2026 review date; current nifedipine page was reviewed May 2026. The 2024 guideline is the publisher version hosted by the University of Birmingham, DOI 10.1093/rheumatology/keae394. BSR partnership and Charity Commission originals were read through their indexed text; direct partnership fetch failed. Full accounts, complete donor ledgers and all supporting-trial finances were not cleared.

• NIAMS: Raynaud overview, July 2024 — Primary/secondary distinction, vessel response and triggers.
• NIAMS: Raynaud assessment/care, July 2024 — Nailfold assessment, medicine review and safe warming.
• NHS: Raynaud, July 2023 — Symptoms and assessment triggers; July 2026 review due date passed.
• NHS: nifedipine, May 2026 — Prescription context, adverse effects and interactions.
• BSR: full 2024 systemic sclerosis guideline — Severe secondary disease and digital-ischemia context; no cleared efficacy ranking.
• NIAMS: systemic sclerosis care, September 2023 — Secondary systemic illness needs organ-specific assessment, not just symptom treatment.
• NIAMS: budget — Congressional funding provenance; proposals are not enacted changes.
• NIAMS: gift authority, June 2024 — Separate Gift Fund accepts individual/organisation donations; complete donors not checked.
• BSR: sponsorship/partnership programme — Institutional route only; no inference a sponsor commissioned this guideline.
• Charity Commission: BSR register — Legal identity and broad institutional income context.
• NCCIH: supplement safety — Interactions and procedure precautions only.
• NHS website: content and funding policy — Website funding and editorial safeguards only.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.